Over the last decade, several large clinical trials have shown that treatment with SGLT2 inhibitors is associated with favorable cardiovascular and renal outcomes in patients with T2DM at risk of or with established cardiovascular disease but also in patients with HF and chronic kidney disease (CKD) without T2DM 9–12. The gene discussed is SLC5A2; the disease is hydrops fetalis.